TORONTO — November 6, 2025 — BiotechReporter.news Medicenna Therapeutics Corp. (Nasdaq:MDNA) has secured US$20 million in private financing from U.S.-based biotech investors, accelerating development of its next-generation interleukin-2 (IL-2) platform …